ANIK FY2025 SEC EDGAR DEF 14A #68 of 86 in industry

Anika Therapeutics, Inc. CEO pay ratio

The CEO earned $4.9M in FY2025 against median worker pay of $112,114 · Measuring Instruments.

Measuring Instruments peers All rankings
State
DE
Filing date
2026-04-28
Industry
Measuring Instruments
Industry rank
#68/86

Data updated August 2026

Subscribe to Anika Therapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
44:1
Below Average (Scale: 0–1000:1)
CEO pay
$4.9M
Median worker
$112,114

Answer first

Anika Therapeutics, Inc.'s FY2025 CEO total of $4.9M ranks #942 of 1,423 complete filings; its 44:1 pay ratio ranks #1029. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $112,114. Industry placement uses the FY2025 SIC-38 peer cohort (# 68 of 86, 22nd percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Measuring Instruments companies.

Dollar rank
#942
$4.9M of 1,423 FY2025
Ratio rank
#1029
44:1 of 1,423
Industry pct
22nd
among the lower quartile of industry peers by pay ratio

How Anika Therapeutics, Inc. ranks nationally

Anika Therapeutics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$4,887,318 34th percentile higher than 34% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). This entry sits in this band. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Anika Therapeutics, Inc. vs. Measuring Instruments peers

CEO total pay ($4.9M) against pay ratio (44:1) for Anika Therapeutics, Inc. (marked) and its 4 closest same-industry peers, against the Measuring Instruments industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02105664.54211328.96316993.48422657.930.7:154.2:177.8:1101.3:1124.8:1CEO total payPay ratio (CEO : median worker)Anika Therapeutics, Inc., CEO total pay: 4887318 · Pay ratio (CEO : median worker): 44:1Anika Therapeutics, Inc.Hurco Companies Inc, CEO total pay: 2008398 · Pay ratio (CEO : median worker): 42:1Hurco Companies IncSI-BONE, Inc., CEO total pay: 181059 · Pay ratio (CEO : median worker): 41:1SI-BONE, Inc.Tactile Systems Technology Inc, CEO total pay: 3444363 · Pay ratio (CEO : median worker): 39:1Tactile Systems Technology IncGlobus Medical Inc, CEO total pay: 128616 · Pay ratio (CEO : median worker): 35:1Globus Medical Inc
Anika Therapeutics, Inc. vs. Measuring Instruments peers, plotted against the industry's $8.0M median CEO total and 121:1 median pay ratio.

Ratio bands among Measuring Instruments peers

Exclusive CEO-to-median-worker bands across 80 complete latest-FY filings in SIC 38. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Anika Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Anika Therapeutics, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
44:1
FY2025
vs prior FY
-7:1
from FY2024 51:1
CEO $ YoY
-4.2%
$4.9M latest
Filings shown
5
FY2021–2025
Anika Therapeutics, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $4.2M - $115,858 36:1 -
2022 $5.9M +41% $119,497 50:1 +14:1
2023 $4.5M -25% $109,550 41:1 -9:1
2024 $5.1M +14% $99,333 51:1 +10:1
2025 $4.9M -4.2% $112,114 44:1 -7:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 898437, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Measuring Instruments

This Company's Ratio
44:1
Industry Median Ratio
121:1
Industry Median CEO Pay
$8.0M
This CEO's Pay
$4.9M
Companies in Industry
86
vs. Industry Median
Below
#68 of 86 by pay ratio in this industry View all companies in Measuring Instruments →

Anika Therapeutics, Inc.: MODEST · MID$ pay ratio

Anika Therapeutics, Inc.'s FY2025 ratio 44:1 ranks #68 of 86 Measuring Instruments filers (22nd percentile). the CEO earned 44× the median employee ($112,114) in FY2025.

Median employee $112,114 (HIGH-MED); MODEST · MID$ stamps put about 44 median-wage years per CEO year.

CEO Total Pay

$4.9M

FY2025 Summary Compensation, below median

Pay Ratio

44:1

Below typical

Anika Therapeutics, Inc. in the lower Measuring Instruments third

Anika Therapeutics, Inc.'s FY2025 ratio 44:1 ranks #68 of 86 Measuring Instruments filers (22nd percentile). The structured pay-ratio disclosure reports the total without line-item components. Measuring Instruments (SIC 38) median ratio is 121:1 across 86 FY2025 filers; Anika Therapeutics, Inc.'s $4.9M CEO total is at or below the $8.0M industry median CEO pay.

Dollar rank #942 and ratio rank #1029 split - treat 44:1 as a disclosure, not a fairness score. Open Measuring Instruments peers.

Key Data, FY2025

Total Compensation
$4.9M
Median Employee Pay
$112,114
Pay Ratio
44:1
Filing Date
2026-04-28

Company Info

Ticker
ANIK
CIK
898437
Industry
Measuring Instruments
SIC Code
3841
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 898437, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Anika Therapeutics, Inc.'s FY2025 ratio 44:1 ranks #68 of 86 Measuring Instruments filers (22nd percentile).

Read with Anika Therapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · MID$ · HIGH-MED.

Vaalco Energy Inc /de/ · MID$

ABS(ceo_total_comp) peer at $4.9M (Δ $5K lighter vs Anika Therapeutics, Inc.); MODEST · HIGH-MED vs this page's MODEST · MID$ · HIGH-MED.
Select Water Solutions, Inc. · MID$

ABS(ceo_total_comp) peer at $4.9M (Δ $16K lighter vs Anika Therapeutics, Inc.); MODEST · HIGH-MED vs this page's MODEST · MID$ · HIGH-MED.
Rogers Corp · MID$

ABS(ceo_total_comp) peer at $4.9M (Δ $24K lighter vs Anika Therapeutics, Inc.); FLOOR · PAR-MED vs this page's MODEST · MID$ · HIGH-MED.
Everus Construction Group, Inc. · MID$

ABS(ceo_total_comp) peer at $4.9M (Δ $25K lighter vs Anika Therapeutics, Inc.); MODEST · HIGH-MED vs this page's MODEST · MID$ · HIGH-MED.
Lemaitre Vascular Inc (SIC 38 pole)

Lemaitre Vascular Inc stamps MODEST · UNFILED nearest in-SIC by ABS(pay_ratio) to Anika Therapeutics, Inc.'s MODEST filing.
National dual ranks · #942/#1029

Anika Therapeutics, Inc.'s FY2025 package sits #942 by CEO dollars and #1029 by ratio under MID$ · MODEST.
Ratio primer · MODEST

Anika Therapeutics, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Anika Therapeutics, Inc. (CIK 898437), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.